Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study

Arthritis Research and Therapy

Volumn 20, Issue 1, 2018, Pages

  Machado, Marina Amaral de Ávila ^a   Moura, Cristiano Soares de ^a   Guerra, Steve Ferreira ^a   Curtis, Jeffrey R ^b   Abrahamowicz, Michal ^a   Bernatsky, Sasha ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b University of Alabama at Birmingham   (United States)

Author keywords

Biologic therapy; Comparative effectiveness research; Disease modifying antirheumatic drug; Rheumatoid arthritis; Tofacitinib

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; CHEMICALLY INDUCED; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; INFECTION; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85044268290     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-018-1539-6     Document Type: Article

References (28)

1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
2. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77.
3. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21(5):409-23.
4. Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457-71.
5. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675-84.
6. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872-85.
7. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-7.
8. Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-9.
9. Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012;15(2):217-30.
10. Gu NY, Huang XY, Fox KM, Patel VD, Baumgartner SW, Chiou CF. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits. 2010;2:351-9.
11. Petri H, Maldonato D, Robinson NJ. Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskelet Disord. 2010;11:247.
12. Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004.
13. Sauer BC, Teng CC, He T, Leng J, Lu CC, Curtis JR, Cannon GW. Effectiveness and costs of biologics in veterans with rheumatoid arthritis. Am J Pharm Benefits. 2015;7(6):280-9.
14. Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ. 2015;18(5):376-89.
15. Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155.
16. Genentech I. Actemra (tocilizumab) prescribing information. South San Francisco, CA: Genentech, Inc.; 2017.
17. UCB, Inc. Cimzia (certolizumab pegol) prescribing information. Smyrna, GA: UCB, Inc.; 2013.
18. Corporation I. Enbrel (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2013.
19. Laboratories A. Humira (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2014.
20. Bristol-Myers Squibb Company. Orencia (abatacept) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
21. Centocor Ortho Biotech, Inc. Remicade (infliximab) prescribing information. Malvern, PA: Centocor Ortho Biotech, Inc.; 2013.
22. Biogen/Genentech USA, Inc. Rituxan (rituximab) prescribing information. South San Francisco, CA: Biogen/Genentech USA, Inc.; 2016.
23. Biotech J. Inc. Simponi (golimumab) prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2014.
24. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-904.
25. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990-7.
26. Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37(3):369-76.
27. Kissin EY. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. Clin Ther. 2014;36(7):1114-6.
28. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401-6.